Active, not recruitingPhase 1NCT02293980
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- MK-3795(drug)
- Enrollment
- 110 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2026
Study locations (25)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of Colorado Cancer Center, Aurora, Colorado, United States
- Yale School of Medicine, New Haven, Connecticut, United States
- University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Emory University Winship Cancer Institue, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
- University of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital - Cancer Center, Boston, Massachusetts, United States
- Beth Israel Deconess Medical Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Mount Sinai Heath System, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- The Ohio State University, Columbus, Ohio, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02293980 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma